{"id":"NCT00965497","sponsor":"University of South Carolina","briefTitle":"Escitalopram (Lexapro) for Depression MS or ALS","officialTitle":"An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (LexaproÂ®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2009-08-25","resultsPosted":"2011-09-07","lastUpdate":"2019-05-01"},"enrollment":13,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depression","Multiple Sclerosis","Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"escitalopram","otherNames":["Lexapro"]}],"arms":[{"label":"Escitalopram","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.","primaryOutcome":{"measure":"Hamilton Depression Scale (HAM-D 17).","timeFrame":"8 weeks","effectByArm":[{"arm":"Escitalopram","deltaMin":15,"sd":7}],"pValues":[{"comp":"OG000","p":"0.01"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["7582177","10227631"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Nausea vomiting and diarrhea"]}}